Log in to save to my catalogue

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f07fb34bcdbc48f7a48a91f7bad56641

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies

About this item

Full title

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies

Publisher

England: BioMed Central Ltd

Journal title

Journal of hematology and oncology, 2025-03, Vol.18 (1), p.30-3, Article 30

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of patients with relapsed/refractory (R/R) hematologic malignancies, including B-cell lymphomas and multiple myeloma (MM). While data pertaining to the efficacy and toxicity associated with CAR-T have been widely reported, there are limited data on long-term complicatio...

Alternative Titles

Full title

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_f07fb34bcdbc48f7a48a91f7bad56641

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f07fb34bcdbc48f7a48a91f7bad56641

Other Identifiers

ISSN

1756-8722

E-ISSN

1756-8722

DOI

10.1186/s13045-025-01676-4

How to access this item